Scarica l'app Stockscreener
2.50
2.72%
-0.07
Dopo l'orario di chiusura:
2.40
-0.10
-4.00%
Precedente Chiudi:
$2.57
Aprire:
$2.55
Volume 24 ore:
68,818
Relative Volume:
0.88
Capitalizzazione di mercato:
$63.50M
Reddito:
$130.00K
Utile/perdita netta:
$-21.29M
Rapporto P/E:
-1.2645
EPS:
-1.977
Flusso di cassa netto:
$-18.29M
1 W Prestazione:
-7.06%
1M Prestazione:
-6.37%
6M Prestazione:
+54.32%
1 anno Prestazione:
-50.20%
Intervallo 1D:
$2.3601
$2.58
Intervallo di 1 settimana:
$2.35
$2.78
Portata 52W:
$1.22
$5.83
Serina Therapeutics Inc Stock (SER) Company Profile
Nome
Serina Therapeutics Inc
Settore
Industria
Telefono
(256) 327-9630
Indirizzo
601 GENOME WAY, HUNTSVILLE
Compare SER vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
2.50 | 65.28M | 130.00K | -21.29M | -18.29M | -1.977 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-14 | Iniziato | H.C. Wainwright | Buy |
Serina Therapeutics Inc Borsa (SER) Ultime notizie
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Serina Therapeutics will present its neurological disease work Sept. 14. - Stock Titan
Serina Therapeutics Announces Independent Committee Recommends Advance of SER-252 Parkinson’s Study to Cohort 2 - Quiver Quantitative
Some Parkinson’s patients showed sustained motor improvement in Serina’s study - Stock Titan
Serina Therapeutics (SER) Dips 2.40% to $2.44, Testing Key Support at $2.32Block Trade Flow - vinanet.vn
Serina Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Serina Therapeutics Establishes Flexible Equity Financing Agreement - The Globe and Mail
Serina Therapeutics Secures $25 Million Equity Financing Facility with Roth Principal - Minichart
Serina Therapeutics Sets Up $25 Million Equity Purchase Facility With Roth Principal Investments - TradingView
IPO Databook: Serina Therapeutics (SER US)Aug 2026 - Smartkarma
Serina TherapeuticsOffers Up To 12,500,000 Shares Of Common Stock By Roth Principal InvestmentsSEC Filing - TradingView
BTIG Maintains Serina Therapeutics(SER.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Serina Therapeutics, Inc. announced that it expects to receive $25 million in funding from Roth Principal Investments, LLC - marketscreener.com
Serina (SER) Move: Ends Lower by 1.53% at $2.58 in the Latest Reading; Next Session: the Near-Term Reference Band Stretches From $2.45 to $2.71 in the Available RecordSwing Entry Signals - vinanet.vn
Serina Therapeutics Q2 loss widens to $(0.55) as revenue drops to zero - scanx.trade
Serina Therapeutics Completes Dosing for 8 Parkinson’s Patients - Stock Titan
Serina Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - Yahoo Finance
Serina Therapeutics Inc (SER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SER Q1 2026 Earnings: Wider Loss Falls Short of Estimates Despite Modest Share GainEarnings Trend Analysis - vinanet.vn
Serina Therapeutics Inc (SER) Stock News Today - TradingKey
Serina Therapeutics (SER) Holds Steady Above $2.24 Support, Up 0.43% in Measured SessionDelta Hedging - vinanet.vn
Serina Therapeutics (SER) Advances 5.83% to $2.18, Approaching Key Resistance at $2.29McClellan Summation - dars.gov.et
SER Q1 2026 Earnings: Wider-than-Expected Loss of -$0.58 per Share Signals Rising Pipeline CostsEarnings Call Highlights - vinanet.vn
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues to Invest in PipelineReturn On Equity - dars.gov.et
Serina Therapeutics Inc (SER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Serina Therapeutics Inc (SER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Serina Therapeutics Inc (SER) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SER|Serina Therapeutics Inc|Price:2.030|Chg%:-0.040 - TradingKey
Serina Therapeutics Market Sentiment - Benzinga España
Serina Therapeutics Inc (SER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Serina Therapeutics Inc (SER) Balance Sheet - TradingKey
Serina Therapeutics, Inc. Revenue Breakdown – AMEX:SER - TradingView
Serina Therapeutics, Inc. Revenue Breakdown – TRADEGATE:2BO - TradingView
TradingKey - TradingKey
Serina Therapeutics Inc (SER) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SER|Serina Therapeutics Inc|Price:1.990|Chg%:-0.080 - TradingKey
Serina Therapeutics to present at BTIG Virtual Biotechnology Conference July 28-29, 2026 - Pluang
Serina Therapeutics, Inc. Amended CEO Employment Agreement and SEC Filing Details – July 2026 - Minichart
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - The Manila Times
Serina Sets July 29 Virtual Investor Meetings at BTIG Event - Stock Titan
Serina Therapeutics (SER) Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue PhaseEarnings Per Share - vinanet.vn
Form 4 Serina Therapeutics Inc For: 23 July By Investing.com - Investing.com Canada
Serina Therapeutics director Simon Farrell files initial beneficial ownership statement - Bitget
Director Simon Farrell awarded 30,500 options at Serina (SER) - Stock Titan
Serina Therapeutics, Inc. (SER) director Simon Farrell files Form 3 - Stock Titan
Serina Therapeutics Amends CEO Employment and Compensation Terms - TipRanks
Serina names Steve Ledger in amended CEO employment agreement - TradingView
Serina’s Parkinson’s trial doses all 8 first-cohort patients - Stock Titan
Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors - TradingView
Serina Therapeutics Adds Industry Veteran to Board - TipRanks
Serina Therapeutics Inc Azioni (SER) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Capitalizzazione:
|
Volume (24 ore):